News Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/01/2026 am IST			5-day change	1st Jan Change
21.46 ^USD	+1.51%		-3.98%	-0.28%

13/01	Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln	RE
13/01	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT

13/01	Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln	RE
13/01	Sector Update: Health Care Stocks Lower in Afternoon Trading	MT
12/01	Sarepta Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 through Jan-16-2026
12/01	Sarepta Therapeutics : 2026 JPMorgan Conference	PU
12/01	Sarepta Preliminary Q4, 2025 Net Product Revenue Miss Estimates; Shares Fall	MT
12/01	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues	BU
12/01	Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty	NE
08/01	Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's disease	AQ
08/01	RBC Raises Price Target on Sarepta Therapeutics to $18 From $16, Keeps Sector Perform, Speculative Risk	MT
07/01	Sarepta Files Trial Application for Huntington's Disease Treatment	MT
07/01	Sarepta Therapeutics, Inc. Announces Submission of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease	CI
07/01	Sarepta Therapeutics announces submission of clinical trial application for SRP-1005	RE
07/01	Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease	BU
05/01	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	BU
01/01	Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
01/01	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
11/12	Sector Update: Health Care Stocks Mixed Premarket Thursday	MT
11/12	Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027	MT
11/12	Sarepta Therapeutics announces refinancing of approximately $291 million of 1.25% convertible senior notes due 2027	RE
11/12	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027	BU
10/12	Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says	MT
09/12	Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says	MT
25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
25/11	Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy	MT
25/11	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Filters